NZ549105A - 3,11b-cis-Dihydrotetrabenazine isomers and pharmaceutical compositions containing them - Google Patents

3,11b-cis-Dihydrotetrabenazine isomers and pharmaceutical compositions containing them

Info

Publication number: NZ549105A
Authority: NZ; New Zealand
Prior art keywords: isomer; dihydrotetrabenazine; compound; isomers; tetrabenazine
Prior art date: 2004-02-11

Application number

NZ549105A

Other languages

English (en)

Inventor

Robert Tridgett

Ian Clarke

Robert Turtle

Grant Johnston

Original Assignee

Cambridge Lab Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-11

Filing date

2005-02-11

Publication date

2009-04-30

2005-02-11 Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd

2009-04-30 Publication of NZ549105A publication Critical patent/NZ549105A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
150000001875 compounds Chemical class 0.000 claims abstract description 75
238000000034 method Methods 0.000 claims abstract description 70
230000008569 process Effects 0.000 claims abstract description 25
-1 Mosher's acid ester Chemical class 0.000 claims abstract description 14
WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 claims description 107
229960005333 tetrabenazine Drugs 0.000 claims description 70
MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims description 69
239000000203 mixture Substances 0.000 claims description 64
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 40
230000000694 effects Effects 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 24
238000006243 chemical reaction Methods 0.000 claims description 18
150000002148 esters Chemical class 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
230000003287 optical effect Effects 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 10
208000000269 Hyperkinesis Diseases 0.000 claims description 8
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 8
239000003153 chemical reaction reagent Substances 0.000 claims description 8
238000007142 ring opening reaction Methods 0.000 claims description 8
230000001624 sedative effect Effects 0.000 claims description 8
206010008748 Chorea Diseases 0.000 claims description 6
208000000323 Tourette Syndrome Diseases 0.000 claims description 6
208000016620 Tourette disease Diseases 0.000 claims description 6
208000020401 Depressive disease Diseases 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
229910052698 phosphorus Inorganic materials 0.000 claims description 5
239000011574 phosphorus Substances 0.000 claims description 5
239000007916 tablet composition Substances 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 4
239000007800 oxidant agent Substances 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
239000007963 capsule composition Substances 0.000 claims description 3
239000012024 dehydrating agents‎ Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
150000004965 peroxy acids Chemical group 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 2
238000000540 analysis of variance Methods 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
230000000887 hydrating effect Effects 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
239000000454 talc Substances 0.000 claims description 2
229910052623 talc Inorganic materials 0.000 claims description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
230000004075 alteration Effects 0.000 claims 2
235000019359 magnesium stearate Nutrition 0.000 claims 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
238000012986 modification Methods 0.000 claims 2
230000004048 modification Effects 0.000 claims 2
238000001061 Dunnett's test Methods 0.000 claims 1
240000008042 Zea mays Species 0.000 claims 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims 1
235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
231100000673 dose–response relationship Toxicity 0.000 claims 1
125000003700 epoxy group Chemical group 0.000 claims 1
230000002296 hyperlocomotor Effects 0.000 claims 1
235000009973 maize Nutrition 0.000 claims 1
235000019698 starch Nutrition 0.000 claims 1
239000008107 starch Substances 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 72
239000000243 solution Substances 0.000 description 71
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
230000002829 reductive effect Effects 0.000 description 43
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
239000007787 solid Substances 0.000 description 38
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
238000011534 incubation Methods 0.000 description 31
238000001914 filtration Methods 0.000 description 28
210000004027 cell Anatomy 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
230000027455 binding Effects 0.000 description 24
239000000543 intermediate Substances 0.000 description 24
102000005962 receptors Human genes 0.000 description 24
108020003175 receptors Proteins 0.000 description 24
229910052943 magnesium sulfate Inorganic materials 0.000 description 23
230000005764 inhibitory process Effects 0.000 description 22
239000000872 buffer Substances 0.000 description 21
235000019341 magnesium sulphate Nutrition 0.000 description 21
241000700159 Rattus Species 0.000 description 20
239000003446 ligand Substances 0.000 description 20
238000002360 preparation method Methods 0.000 description 19
239000002904 solvent Substances 0.000 description 19
238000012360 testing method Methods 0.000 description 18
239000003981 vehicle Substances 0.000 description 18
241000282414 Homo sapiens Species 0.000 description 17
238000003556 assay Methods 0.000 description 17
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 16
239000002253 acid Substances 0.000 description 16
150000001336 alkenes Chemical class 0.000 description 16
238000000853 optical rotatory dispersion Methods 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
239000000377 silicon dioxide Substances 0.000 description 16
230000009870 specific binding Effects 0.000 description 16
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 15
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 14
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 13
102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 13
238000010521 absorption reaction Methods 0.000 description 13
239000003921 oil Substances 0.000 description 13
235000019198 oils Nutrition 0.000 description 13
239000000047 product Substances 0.000 description 13
239000002287 radioligand Substances 0.000 description 13
238000006722 reduction reaction Methods 0.000 description 13
230000000638 stimulation Effects 0.000 description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
230000009467 reduction Effects 0.000 description 12
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 11
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 11
238000004296 chiral HPLC Methods 0.000 description 11
235000019441 ethanol Nutrition 0.000 description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
230000035699 permeability Effects 0.000 description 10
238000010992 reflux Methods 0.000 description 10
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
238000004440 column chromatography Methods 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
108010078791 Carrier Proteins Proteins 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 8
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
229910000085 borane Inorganic materials 0.000 description 8
229940079593 drug Drugs 0.000 description 8
150000002118 epoxides Chemical group 0.000 description 8
238000004128 high performance liquid chromatography Methods 0.000 description 8
238000006460 hydrolysis reaction Methods 0.000 description 8
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
229960003604 testosterone Drugs 0.000 description 8
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
102000010909 Monoamine Oxidase Human genes 0.000 description 7
108010062431 Monoamine oxidase Proteins 0.000 description 7
239000012131 assay buffer Substances 0.000 description 7
239000002585 base Substances 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229960003878 haloperidol Drugs 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000012071 phase Substances 0.000 description 7
229910000029 sodium carbonate Inorganic materials 0.000 description 7
238000003756 stirring Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
239000012981 Hank's balanced salt solution Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
235000010323 ascorbic acid Nutrition 0.000 description 6
229960005070 ascorbic acid Drugs 0.000 description 6
239000011668 ascorbic acid Substances 0.000 description 6
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
238000007912 intraperitoneal administration Methods 0.000 description 6
230000006742 locomotor activity Effects 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
239000003208 petroleum Substances 0.000 description 6
229960004889 salicylic acid Drugs 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000007858 starting material Substances 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
206010058504 Ballismus Diseases 0.000 description 5
102000006378 Catechol O-methyltransferase Human genes 0.000 description 5
108020002739 Catechol O-methyltransferase Proteins 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
108050004812 Dopamine receptor Proteins 0.000 description 5
102000015554 Dopamine receptor Human genes 0.000 description 5
208000012661 Dyskinesia Diseases 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 5
238000006297 dehydration reaction Methods 0.000 description 5
230000028436 dopamine uptake Effects 0.000 description 5
238000006735 epoxidation reaction Methods 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000002329 infrared spectrum Methods 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
238000004949 mass spectrometry Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000000159 protein binding assay Methods 0.000 description 5
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 5
239000002356 single layer Substances 0.000 description 5
238000001228 spectrum Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 4
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
208000023105 Huntington disease Diseases 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 4
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 4
WEQLWGNDNRARGE-UHFFFAOYSA-N b-Dihydrotetrabenazine Chemical compound C1CN2CC(CC(C)C)C(O)CC2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
230000018044 dehydration Effects 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
239000006260 foam Substances 0.000 description 4
238000001640 fractional crystallisation Methods 0.000 description 4
238000002825 functional assay Methods 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
238000006197 hydroboration reaction Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
210000004129 prosencephalon Anatomy 0.000 description 4
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
229960003147 reserpine Drugs 0.000 description 4
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000007921 spray Substances 0.000 description 4
210000002504 synaptic vesicle Anatomy 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
229920002873 Polyethylenimine Polymers 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
208000010513 Stupor Diseases 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000001800 adrenalinergic effect Effects 0.000 description 3
150000008044 alkali metal hydroxides Chemical class 0.000 description 3
239000000935 antidepressant agent Substances 0.000 description 3
229940005513 antidepressants Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
238000001816 cooling Methods 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
210000000744 eyelid Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000005484 gravity Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
239000005457 ice water Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
238000001819 mass spectrum Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
JJYKJUXBWFATTE-UHFFFAOYSA-N mosher's acid Chemical compound COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 3
239000001472 potassium tartrate Substances 0.000 description 3
229940111695 potassium tartrate Drugs 0.000 description 3
235000011005 potassium tartrates Nutrition 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
238000002953 preparative HPLC Methods 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
239000003586 protic polar solvent Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
JJYKJUXBWFATTE-SECBINFHSA-N (2r)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid Chemical compound CO[C@](C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-SECBINFHSA-N 0.000 description 2
OFCNTYBPPAQCRE-UHFFFAOYSA-N 3-(2-aminoethyl)-3h-indol-5-ol Chemical compound C1=C(O)C=C2C(CCN)C=NC2=C1 OFCNTYBPPAQCRE-UHFFFAOYSA-N 0.000 description 2
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
RNXYXIKLWRRZNU-UHFFFAOYSA-N Kynuramine Natural products NCCCC(=O)C1=CC=CC=N1 RNXYXIKLWRRZNU-UHFFFAOYSA-N 0.000 description 2
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
206010029216 Nervousness Diseases 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
108091006772 SLC18A1 Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000037007 arousal Effects 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
239000000498 cooling water Substances 0.000 description 2
239000002178 crystalline material Substances 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
229940081763 haloperidol 1 mg Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000036571 hydration Effects 0.000 description 2
HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 2
229950001476 idazoxan Drugs 0.000 description 2
229960003998 ifenprodil Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000008517 inhibition of serotonin uptake Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000010354 integration Effects 0.000 description 2
QLPVTIQQFGWSQQ-UHFFFAOYSA-N kynuramine Chemical compound NCCC(=O)C1=CC=CC=C1N QLPVTIQQFGWSQQ-UHFFFAOYSA-N 0.000 description 2
239000010410 layer Substances 0.000 description 2
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
108010052968 leupeptin Proteins 0.000 description 2
238000011068 loading method Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
230000018791 negative regulation of catalytic activity Effects 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
201000003004 ptosis Diseases 0.000 description 2
238000000746 purification Methods 0.000 description 2
PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 2
238000011084 recovery Methods 0.000 description 2
SIIICDNNMDMWCI-YJNKXOJESA-N rti-55 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(I)C=C1 SIIICDNNMDMWCI-YJNKXOJESA-N 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
230000013275 serotonin uptake Effects 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000012265 solid product Substances 0.000 description 2
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
GWNKOGCQUQKSHT-UHFFFAOYSA-N 2,9,10-trimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine Chemical compound COC1=C(OC)C=C2C3CC(OC)C(CC(C)C)CN3CCC2=C1 GWNKOGCQUQKSHT-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
YGSDEFSMJLZEOE-RHRFEJLCSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)[14C]1=CC=CC=C1O YGSDEFSMJLZEOE-RHRFEJLCSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
241000252206 Cypriniformes Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108090000525 Dopamine D3 Receptors Proteins 0.000 description 1
102000004073 Dopamine D3 Receptors Human genes 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
239000004425 Makrolon Substances 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
GOTMKOSCLKVOGG-UHFFFAOYSA-N SCH 23390 Chemical compound C1N(C)CCC2=CC(Cl)=C(O)C=C2C1C1=CC=CC=C1 GOTMKOSCLKVOGG-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000007605 air drying Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
229910000091 aluminium hydride Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000007894 caplet Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
108010017146 dopamine D2L receptor Proteins 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
210000000110 microvilli Anatomy 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229960001073 nomifensine Drugs 0.000 description 1
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000003431 oxalo group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
GRONZTPUWOOUFQ-UHFFFAOYSA-M sodium;methanol;hydroxide Chemical compound [OH-].[Na+].OC GRONZTPUWOOUFQ-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008259 solid foam Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000011916 stereoselective reduction Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000016686 tic disease Diseases 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NZ549105A 2004-02-11 2005-02-11 3,11b-cis-Dihydrotetrabenazine isomers and pharmaceutical compositions containing them NZ549105A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US54353104P	2004-02-11	2004-02-11
GB0403037A GB2410947B (en)	2004-02-11	2004-02-11	Pharmaceutical compounds
PCT/GB2005/000464 WO2005077946A1 (fr)	2004-02-11	2005-02-11	Dihydrotetrabenazines et compositions pharmaceutiques les contenant

Publications (1)

Publication Number	Publication Date
NZ549105A true NZ549105A (en)	2009-04-30

Family

ID=32011732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ549105A NZ549105A (en)	2004-02-11	2005-02-11	3,11b-cis-Dihydrotetrabenazine isomers and pharmaceutical compositions containing them

Country Status (23)

Country	Link
US (1)	US20080108645A1 (fr)
EP (1)	EP1716145B1 (fr)
JP (1)	JP2007522193A (fr)
CN (1)	CN100591680C (fr)
AT (1)	ATE406370T1 (fr)
AU (1)	AU2005213525B2 (fr)
CA (1)	CA2555815A1 (fr)
CY (1)	CY1108592T1 (fr)
DE (1)	DE602005009327D1 (fr)
DK (1)	DK1716145T3 (fr)
ES (1)	ES2313292T3 (fr)
GB (1)	GB2410947B (fr)
HK (1)	HK1098138A1 (fr)
HR (1)	HRP20080564T3 (fr)
MX (1)	MXPA06009164A (fr)
NZ (1)	NZ549105A (fr)
PL (1)	PL1716145T3 (fr)
PT (1)	PT1716145E (fr)
RS (1)	RS50660B (fr)
RU (1)	RU2365590C2 (fr)
SI (1)	SI1716145T1 (fr)
WO (1)	WO2005077946A1 (fr)
ZA (1)	ZA200607425B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2843590B1 (fr)	2002-08-14	2007-10-05	Prestwick Scient Capital Inc	Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
GB0514501D0 (en)	2005-07-14	2005-08-24	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
GB0516168D0 (en) *	2005-08-05	2005-09-14	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
RU2407743C2 (ru) *	2005-08-06	2010-12-27	Байовейл Лэборетериз Интернешнл (Барбадос) Срл	Фармацевтические соединения
MX2008014064A (es) *	2006-05-02	2009-06-12	Univ Pennsylvania	Derivados radiomarcados de dihidrotetrabenazina y su uso como agentes de diagnostico por imagenes.
EP2081929B1 (fr)	2006-11-08	2013-01-09	Neurocrine Biosciences, Inc.	Composés 3-isobutyl-9, 10-diméthoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol substitués et procédés associés
US7897770B2 (en)	2007-10-25	2011-03-01	General Electric Company	Fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897769B2 (en)	2007-10-25	2011-03-01	General Electric Company	Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
WO2009055520A2 (fr) *	2007-10-25	2009-04-30	General Electric Company	Agents d'imagerie à base d'éther de dihydrotétrabénazine fluoré et sondes
GB0721669D0 (en) *	2007-11-02	2007-12-12	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
US7910738B2 (en)	2007-11-29	2011-03-22	General Electric Company	Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7902364B2 (en)	2007-11-29	2011-03-08	General Electric Company	Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en)	2007-11-29	2011-11-08	General Electric Company	Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US8013161B1 (en)	2007-12-07	2011-09-06	General Electric Company	Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
CN101889013B (zh) *	2007-12-07	2014-09-03	通用电气公司	作为成像剂和探针的氟烷基丁苯那嗪甲醇化合物
US7919622B2 (en)	2007-12-07	2011-04-05	Kande Kankanamalage Dayarathna Amarasinghe	Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
GB0810857D0 (en) *	2008-06-13	2008-07-23	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
US20110053866A1 (en) *	2008-08-12	2011-03-03	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
US20120208773A1 (en) *	2008-08-12	2012-08-16	Valeant International (Barbados) Srl	Pharmaceutical compositions with tetrabenazine
GB2462611A (en) *	2008-08-12	2010-02-17	Cambridge Lab	Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) *	2008-09-08	2010-03-17	Cambridge Lab	Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en)	2008-09-08	2010-03-17	Cambridge Lab	3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) *	2008-09-08	2010-03-10	Cambridge Lab	3,11b-cis-dihydrotetrabenazine for use in treating asthma
WO2010044981A2 (fr) *	2008-09-18	2010-04-22	Auspex Pharmaceutical ,Inc.	Inhibiteurs benzoquinoline du transporteur de monoamines vésiculaire 2
CA2771539A1 (fr)	2009-08-12	2011-02-17	Valeant International (Barbados) Srl	Compositions pharmaceutiques
CN103003275A (zh) *	2010-06-01	2013-03-27	奥斯拜客斯制药有限公司	Vmat2的苯并喹啉酮抑制剂
CN102285984B (zh) *	2010-11-25	2012-10-10	江苏威凯尔医药科技有限公司	(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
US9550780B2 (en)	2012-09-18	2017-01-24	Auspex Pharmaceuticals, Inc.	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja)	2012-09-18	2018-07-25	オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
JP2016506957A (ja) *	2013-01-31	2016-03-07	オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｖｍａｔ２のベンゾキノロン阻害剤
MX369956B (es)	2013-12-03	2019-11-27	Auspex Pharmaceuticals Inc	Metodos para preparar compuestos de benzoquinolina.
EA201691512A1 (ru)	2014-01-27	2017-01-30	Оспекс Фармасьютикалз, Инк.	Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
CA2938581C (fr) *	2014-02-07	2023-02-28	Neurocrine Biosciences, Inc.	Compositions pharmaceutiques comprenant un medicament antipsychotique et un inhibiteur de vmat2 et utilisations de celles-ci
WO2015120110A2 (fr)	2014-02-07	2015-08-13	Auspex Pharmaceuticals, Inc.	Nouvelles formulations pharmaceutiques
MX2017011459A (es)	2015-03-06	2018-04-24	Auspex Pharmaceuticals Inc	Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
CN113713108A (zh) *	2015-06-23	2021-11-30	纽罗克里生物科学有限公司	用于治疗神经学疾病或病症的vmat2抑制剂
CA3002074A1 (fr)	2015-10-30	2017-05-04	Neurocrine Biosciences, Inc.	Sels de valbenazine et polymorphes associes
JP6869988B2 (ja)	2015-12-23	2021-05-12	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
TW202345829A (zh)	2016-12-02	2023-12-01	美商紐羅克里生物科學有限公司	戊苯那嗪（valbenazine）於治療精神*症或情感性精神*症之用途
CN110769826A (zh)	2017-01-27	2020-02-07	纽罗克里生物科学有限公司	施用某些vmat2抑制剂的方法
WO2018164996A1 (fr)	2017-03-06	2018-09-13	Neurocrine Biosciences, Inc.	Posologie pour la valbénazine
JP7250692B2 (ja) *	2017-04-01	2023-04-03	アデプティオファーマシューティカルズリミテッド	運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705303D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
RU2771164C2 (ru) *	2017-04-01	2022-04-27	Адептио Фармасьютикалз Лимитед	(+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
GB201705302D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705306D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705304D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
US20200179352A1 (en)	2017-04-26	2020-06-11	Neurocrine Biosciences, Inc.	Use of valbenazine for treating levodopa-induced dyskinesia
CN107089980B (zh) *	2017-05-11	2019-08-30	合肥工业大学	一种手性苯并[a]喹嗪-2-酮类化合物及其不对称催化合成方法
EP3684333A2 (fr)	2017-09-21	2020-07-29	Neurocrine Biosciences, Inc.	Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
AU2017435893B2 (en) *	2017-10-10	2023-06-29	Neurocrine Biosciences, Inc	Methods for the administration of certain VMAT2 inhibitors
US10993941B2 (en)	2017-10-10	2021-05-04	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
EP3806856A1 (fr)	2018-06-14	2021-04-21	Neurocrine Biosciences, Inc.	Composés inhibiteurs de vmat2, compositions et méthodes associées
BR112021000019A2 (pt)	2018-08-15	2021-04-06	Neurocrine Biosciences Inc.	Métodos para administração de certos inibidores de vmat2
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
EP4168409A1 (fr)	2021-03-22	2023-04-26	Neurocrine Biosciences, Inc.	Inhibiteurs de vmat2 et procédés d'utilisation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3314966A (en) *		1967-04-18		Substituted benzo[a]quinolizines
US2954382A (en) *		1960-09-27		Xpreparation of hexahydrobenzoquinol-
US3009918A (en) *		1961-11-21		Chz ch
US3132147A (en) *		1964-05-05
US3095419A (en) *		1963-06-25		Process for preparing z-oxo-j-
US2830993A (en) *		1958-04-15		Quinolizine derivatives
US3079395A (en) *		1963-02-26		Novel z-oxq-benzoquinoliaine
US2843591A (en) *		1958-07-15		Method for preparing same
US3053845A (en) *		1962-09-11		Benzofykedocolines
US3209005A (en) *		1965-09-28		Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3123609A (en) *		1964-03-03		Benzo
US3159638A (en) *		1964-12-01		Xcha-chj
US3045021A (en) *	1959-09-24	1962-07-17	Hoffmann La Roche	Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) *	1959-11-24	1965-07-21	Wellcome Found	Method for making benzo(a)-quinolizine derivatives
US3375254A (en) *	1961-09-29	1968-03-26	Burroughs Wellcome Co	Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) *	1961-12-29	1963-09-24	Pfizer & Co C	10-aminobenzopyridocolines
US3390152A (en) *	1965-10-21	1968-06-25	Abbott Lab	9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3634431A (en) *	1969-12-22	1972-01-11	Miles Lab	Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
US3635986A (en) *	1969-12-22	1972-01-18	Miles Lab	2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) *	1974-10-23	1982-05-31	Chinoin Gyogyszer Es Vegyeszet	Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) *	1975-05-22	1978-06-14	Wyeth John & Brother Ltd	1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) *	1975-11-21	1979-01-09	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Process for producing benzo (a) quinolizine derivatives
US4304913A (en) *	1978-11-20	1981-12-08	Miles Laboratories, Inc.	Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) *	1980-10-14	1982-10-12	Xerox Corporation	Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) *	1982-10-08	1988-10-18	Glaxo Group Limited	Pack for administering medicaments to patients
NO166268C (no) *	1985-07-30	1991-07-03	Glaxo Group Ltd	Innretning for administrering av medikamenter til pasienter.
GB9004781D0 (en) *	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
US6087376A (en) *	1997-02-05	2000-07-11	University Of Kentucky Research Foundation	Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) *	1999-06-11	2005-06-03	Sanofi Synthelabo	Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) *	2000-01-14	2003-10-14	Biolife Solutions, Inc.	Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2001079198A1 (fr) *	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles permettant d'inhiber des proteines kinases
EP1638529B1 (fr) *	2003-06-16	2016-08-10	ANDRX Pharmaceuticals, LLC.	Composition orale a liberation prolongee
KR100682506B1 (ko) *	2005-01-18	2007-02-15	(주)젠크로스	프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) *	2005-07-14	2005-08-24	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
GB0516168D0 (en) *	2005-08-05	2005-09-14	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
GB0810857D0 (en) *	2008-06-13	2008-07-23	Cambridge Lab Ireland Ltd	Pharmaceutical compounds
GB2462611A (en) *	2008-08-12	2010-02-17	Cambridge Lab	Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) *	2008-08-12	2011-03-03	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
GB2463452A (en) *	2008-09-08	2010-03-17	Cambridge Lab	Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) *	2008-09-08	2010-03-17	Cambridge Lab	3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) *	2008-09-08	2010-03-10	Cambridge Lab	3,11b-cis-dihydrotetrabenazine for use in treating asthma

2004
- 2004-02-11 GB GB0403037A patent/GB2410947B/en not_active Expired - Fee Related
2005
- 2005-02-11 RU RU2006132329/04A patent/RU2365590C2/ru not_active IP Right Cessation
- 2005-02-11 JP JP2006552683A patent/JP2007522193A/ja active Pending
- 2005-02-11 AT AT05708289T patent/ATE406370T1/de active
- 2005-02-11 NZ NZ549105A patent/NZ549105A/en not_active IP Right Cessation
- 2005-02-11 PT PT05708289T patent/PT1716145E/pt unknown
- 2005-02-11 US US10/597,803 patent/US20080108645A1/en not_active Abandoned
- 2005-02-11 CA CA002555815A patent/CA2555815A1/fr not_active Abandoned
- 2005-02-11 PL PL05708289T patent/PL1716145T3/pl unknown
- 2005-02-11 SI SI200530470T patent/SI1716145T1/sl unknown
- 2005-02-11 WO PCT/GB2005/000464 patent/WO2005077946A1/fr active Application Filing
- 2005-02-11 ZA ZA200607425A patent/ZA200607425B/xx unknown
- 2005-02-11 RS RSP-2008/0550A patent/RS50660B/sr unknown
- 2005-02-11 EP EP05708289A patent/EP1716145B1/fr active Active
- 2005-02-11 ES ES05708289T patent/ES2313292T3/es active Active
- 2005-02-11 DE DE602005009327T patent/DE602005009327D1/de active Active
- 2005-02-11 MX MXPA06009164A patent/MXPA06009164A/es active IP Right Grant
- 2005-02-11 CN CN200580012044A patent/CN100591680C/zh not_active Expired - Fee Related
- 2005-02-11 DK DK05708289T patent/DK1716145T3/da active
- 2005-02-11 AU AU2005213525A patent/AU2005213525B2/en not_active Ceased
2007
- 2007-04-25 HK HK07104428.7A patent/HK1098138A1/xx not_active IP Right Cessation
2008
- 2008-11-06 HR HR20080564T patent/HRP20080564T3/xx unknown
- 2008-11-26 CY CY20081101360T patent/CY1108592T1/el unknown

Also Published As

Publication number	Publication date
GB2410947B (en)	2008-09-17
ATE406370T1 (de)	2008-09-15
EP1716145A1 (fr)	2006-11-02
DE602005009327D1 (de)	2008-10-09
CN100591680C (zh)	2010-02-24
ZA200607425B (en)	2008-02-27
PT1716145E (pt)	2008-11-14
HK1098138A1 (en)	2007-07-13
CA2555815A1 (fr)	2005-08-25
HRP20080564T3 (en)	2009-02-28
WO2005077946A1 (fr)	2005-08-25
AU2005213525B2 (en)	2011-01-06
MXPA06009164A (es)	2007-01-26
RU2365590C2 (ru)	2009-08-27
RS50660B (sr)	2010-06-30
GB0403037D0 (en)	2004-03-17
RU2006132329A (ru)	2008-03-20
CN1980924A (zh)	2007-06-13
EP1716145B1 (fr)	2008-08-27
GB2410947A (en)	2005-08-17
ES2313292T3 (es)	2009-03-01
SI1716145T1 (sl)	2009-02-28
DK1716145T3 (da)	2008-11-10
US20080108645A1 (en)	2008-05-08
AU2005213525A1 (en)	2005-08-25
CY1108592T1 (el)	2014-04-09
PL1716145T3 (pl)	2009-04-30
JP2007522193A (ja)	2007-08-09

Legal Events

Date	Code	Title	Description
2009-09-25	PSEA	Patent sealed
2009-09-25	RENW	Renewal (renewal fees accepted)
2009-11-27	ASS	Change of ownership	Owner name: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) , BB Free format text: OLD OWNER(S): CAMBRIDGE LABORATORIES (IRELAND) LIMITED
2015-08-28	LAPS	Patent lapsed

Publication	Publication Date	Title
EP1716145B1 (fr)	2008-08-27	Dihydrotetrabenazines et compositions pharmaceutiques les contenant
RU2409365C2 (ru)	2011-01-20	ПРИМЕНЕНИЕ 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА
EP2649069B1 (fr)	2015-08-26	Dérivés de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP2661435B1 (fr)	2015-08-19	Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
EP1861100B1 (fr)	2008-10-29	3,11 b-cis-dihydrotetrabenazine pour le traitement d'une maladie proliferative ou d'une inflammation
EP2643320B1 (fr)	2015-03-04	Dérivés de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2
GB2463452A (en)	2010-03-17	Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
KR20080033500A (ko)	2008-04-16	정신분열증 및 기타 정신병의 치료를 위한 3,11ｂ 시스 디히드로테트라베나진
CA2220407A1 (fr)	1997-10-09	Diazepino-indoles inhibiteurs de phosphodiesterases 4
IL45938A (en)	1977-12-30	History of benzomorphan and benzomorphinan, their preparation and pharmaceutical preparations containing them
US20110190333A1 (en)	2011-08-04	Dihydrotetrabenanzine for the treatment of anxiety
KR20150115809A (ko)	2015-10-14	이소메텝텐 이성질체
WO2006019660A2 (fr)	2006-02-23	(1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
KR20070023666A (ko)	2007-02-28	디하이드로테트라베나진 및 이를 함유하는 약학 조성물
KR20010014294A (ko)	2001-02-26	(Ｓ) 2-메틸아미노-2-페닐-ｎ-부틸3,4,5-트리메톡시벤조에이트 및 만성 통증을 치료하기위한 그의 용도